tbuckley/cabot-search huggingface dataset:
Rituximab-CHOP (R-CHOP) and Radiotherapy (RT) for Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).
Authors: Theodoros P. Vassilakopoulos, Maria K. Angelopoulou, Zacharoula Galani, Sotirios Sachanas, Andreas Katsigiannis, Effimia Vrakidou, Christos Poziopoulos, Nikos Constantinou, Panayiotis Repoussis, Maria N. Dimopoulou, Stiliani I. Kokoris, Evridiki Michali, Evangelia M. Dimitriadou, Marina P. Siakantaris, Flora N. Kontopidou, Christina Kalpadaki, Nora-Athina Viniou, Elias Kyriakou, Penelope Korkolopoulou, Marie-Christine Kyrtsonis, Panayiotis Panayiotidis, Paraskevi Roussou, Gerassimos A. Pangalis
Journal: Blood (2006)
PGE2 Promotes BM Hematopoietic Stem Cell Retention Via Stromal Lactate Production­­­­, cAMP and CXCL12/CXCR4 Regulation
Authors: Anju Kumari, Aya Ludin, Karin Golan, Orit Kollet, Elisabeth Niemeyer, Nitzan Friedlander, Tsvee Lapidot
Journal: Blood (2014)
Oncolytic Adenovirus Expressing Cytokines Enhances Anti-Tumor Efficacy of Mesothelin-Redirected CAR-T Cells
Authors: Keisuke Watanabe, Sonia Guedan, John Scholler, Shannon McGettigan, Yangpin Luo, Siri Tähtinen, Suvi Parviainen, Riikka Havunen, Mikko Siurala, Akseli Hemminki, Carl H June
Journal: Blood (2016)
Fertility Preservation in Pediatric and Adolescent Patients Undergoing HSCT: a Cross-Sectional Survey of the EBMT Pediatric WP
Authors: Tamara Diesch, Alicia Rovo, Nicolas von der Weid, Maura Faraci, Marta Pillon, Arnaud Dalissier, Jean-Hugues Dalle, Peter Bader
Journal: Blood (2016)
Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF,
Authors: Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Alan Shields, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Thomas Hare, Sue Erickson-Viitanen, William Sun, Victor A. Sandor, Richard S. Levy, Hagop M. Kantarjian, Srdan Verstovsek
Journal: Blood (2011)
Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children’s Oncology Group Study.
Authors: Robert P. Castleberry, Mignon L. Loh, Nalini Jayaprakash, April Peterson, Vicky Casey, Myron Chang, Brigitte Widemann, Peter D. Emanuel
Journal: Blood (2005)
Mixed Chimerism Following Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease Prevents Intravascular Hemolysis and Restores Endothelial Function.
Authors: Catherine J. Wu, Mark T. Gladwin, Lakshamanan Krishnamurti, Melinda Biernacki, Shelby A. Rogers, Xunde Wang, Joseph H. Antin, Jerome Ritz
Journal: Blood (2004)
Evaluation of Thrombin Generation in the Early Stages of Sepsis in Patients with Hematological Malignancies and Febrile Neutropenia,
Authors: Susan K Picoli-Quaino, Brunna E Alves, Francisco J P Aranha, Irene Lorand-Metze, Carmino Antonio De Souza, Joyce M Annichino-Bizzacchi, Erich V De Paula
Journal: Blood (2011)
Overproduction of inter-α-trypsin inhibitor heavy chain 1 after loss of Gα <sub>13</sub> in liver exacerbates systemic insulin resistance in mice
Authors: Tae Hyun Kim, Ja Hyun Koo, Mi Jeong Heo, Chang Yeob Han, Yong-In Kim, Shi-Young Park, Il Je Cho, Chang Ho Lee, Cheol Soo Choi, Jung Weon Lee, Won Kim, Je-Yoel Cho, Sang Geon Kim
Journal: Science Translational Medicine (2019)

Loss of Gα 13 boosts production of liver ITIH1, resulting in systemic insulin resistance in mice that is reversed by ITIH1 neutralization by antibody.
Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)
Authors: Michael R. Savona, Olatoyosi Odenike, Philip C. Amrein, David P. Steensma, Wael A. Harb, Amy E. DeZern, Laura C. Michaelis, Stefan Faderl, James N. Lowder, Pietro Taverna, Aram Oganesian, Richa Dua, Roya Nawabi, Mohammad Azab, Guillermo Garcia-Manero
Journal: Blood (2015)
CNTO328 (Anti-IL-6 mAb) Treatment Is Associated with An Increase in Hemoglobin (Hb) and Decrease in Hepcidin Levels in Renal Cell Carcinoma (RCC).
Authors: Martin Schipperus, Britte Rijnbeek, Manjula Reddy, Xiang Qin, Mark J. Cornfeld
Journal: Blood (2009)
Optimization of Bcl11a Knockdown By miRNA Scaffold Embedded Shrnas Leading to Enhanced Induction of Fetal Hemoglobin in Erythroid Cells for the Treatment of Beta-Hemoglobinopathies
Authors: Christian Brendel, Swaroopa Guda, Raffaele Renella, Peng Du, Daniel E. Bauer, Matthew C. Canver, Sophia C. Kamran, James Thornton, Helen de Boer, Michael D. Milsom, Stuart H. Orkin, Richard Gregory, David A. Williams
Journal: Blood (2014)
Circulating Adiponectin and Markers of Endothelial and Cardiovascular Dysfunction Correlate with Disease Burden in Newly Diagnosed Patients with Multiple Myeloma; Increase of Adiponectin after Bortezomib- and IMiD-Based Regimens
Authors: Evangelos Terpos, Ioannis Papassotiriou, Efstathios Kastritis, Gerasimos-Petros Papassotiriou, Dimitrios Christoulas, Nikolaos Kanellias, Anna Komitopoulou, Evangelos Eleutherakis-Papaiakovou, Ioannis Panagiotidis, Maria Gavriatopoulou, Emilia Mantzou, Meletios A. Dimopoulos
Journal: Blood (2016)
Three Novel Alternative Splicing Mutations in BCR-ABL1 detected in CML Patients with Resistance to Kinase Inhibitors.
Authors: Wanlong Ma, Hagop Kantarjian, Jorge Cortes, XI Zhang, Xiuqiang Wang, Zhong Zhang, Chen-Hsiung Yeh, Anthony Sferruzza, Susan O'Brien, Maher Albitar
Journal: Blood (2009)
Incidence of Disease Transformation and Development of MDS/AML in 165 Patients with Waldenström’s Macroglobulinemia (WM) Treated with Fludarabine (F)-Based Regimen in Three Studies (French Cooperative Group on CLL/WM)
Authors: Veronique Leblond, Jerome Tamburini, Vincent Levy, Sylvain Choquet, Anne Laure Taksin, Frederic Maloisel, Pierre Morel
Journal: Blood (2007)
Eradication of Recipient CMV Specific T Cells by Donor Lymphocyte Infusion Does Not Impair Protective Immunity In Patients Transplanted with a CMV Negative Donor Due to An Early Donor Derived Primary CMV Specific T Cell Response
Authors: Pim L.J. van der Heiden, Jessica C. Harskamp, Esther H.M. van Egmond, Piëtte P. Deutz-Terlouw, J.H. Frederik Falkenburg, Erik W.A. Marijt
Journal: Blood (2010)
Multiple Roles for the Zebrafish Homologue of the Murine Evi1 Gene during Primitive Myelopoiesis and HSC Development
Authors: Martina Konantz, Sarah Grzywna, Tamara C Pereboom, Kelli J. Carroll, Virginie Esain, Lothar Kanz, Trista E North, Claudia Lengerke
Journal: Blood (2014)
Escalated activation ofSTAT3 due to JAK2 V617F activatingmutation causesdownregulation ofPTEN via miRNA 21overexpression
Authors: Mamta P. Sumi, Sameer A. Guru, Rashid Mir, Imtiyaz Najar, Mariyam Zuberi, Naresh K. Gupta, Pramod Lali, Alpana Saxena
Journal: Annals of Oncology (2019)
The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial
Authors: Charlotte Pawlyn, David Cairns, Martin Kaiser, Alina Striha, John Jones, Vallari Shah, Matthew Jenner, Mark Drayson, Roger Owen, Walter Gregory, Gordon Cook, Gareth Morgan, Graham Jackson, Faith Davies
Journal: Leukemia (2019)

Abstract Disease factors such as tumor burden and molecular risk affect myeloma patient outcomes as well as patient factors that impact the capacity to deliver treatment. How the relative importance of these factors changes with patient age has not previously been investigated comprehensively. We analyzed data from 3894 patients of all ages uniformly treated in a large clinical trial of myeloma patients, Myeloma XI. Even with novel therapeutic approaches progression-free survival (PFS) and overall survival (OS) are affected by age with a stepwise reduction in PFS and OS with each decade increase. Renal function deteriorated with increasing age whilst the frequency of t (4;14) and del(17p) decreased and gain(1q) increased. The relative contribution of performance status, international staging score and molecular risk to progression-free and overall survival varied by age group. Molecular events have a larger effect on outcome in younger patients with their relative contribution diminishing in the elderly. Performance status is important for patient outcome at all ages suggesting that physical frailty may be a more important predictor of outcome than age itself. Significant differences in the factors driving patient outcomes at different ages are important to consider as we design disease segmentation strategies to deliver personalized treatment approaches.
SNP-Arrays Provide New Insights Into the Pathogenesis of Post-Transplant Diffuse Large B-Cell Lymphoma (PT-DLBCL).
Authors: Andrea Rinaldi, Daniela Capello, Marta Scandurra, Timothy C. Greiner, Wing C. Chan, Davide Rossi, Govind Bhagat, Marco Paulli, Giorgio Inghirami, Maurilio Ponzoni, Santiago Montes Moreno, Miguel A. Piris, Michael Mian, Paola M.V. Rancoita, Emanuele Zucca, Riccardo Dalla-Favera, Gianluca Gaidano, Ivo Kwee, Francesco Bertoni
Journal: Blood (2009)
NPM1-TYK2 Fusion Is an Oncogene and a Novel HSP90-Client Protein
Authors: Sudhakiranmayi Kuravi, Preethi Kunchala, Siddhartha Ganguly, Sunil Abhyankar, Yogen Saunthararajah, Kojo S. J. Elenitoba-Johnson, Jensen Roy, Joseph McGuirk, Ramesh Balusu
Journal: Blood (2016)
Telomere Shortening Promotes Chromosomal Instability and Predicts Malignant Clonal Evolution in Aplastic Anemia.
Authors: Rodrigo T. Calado, James N Cooper, Phillip Scheinberg, Colin Wu, Marco A Zago, Hesed Padilla-Nash, Thomas Ried, Elaine M Sloand, Neal S Young
Journal: Blood (2009)
Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study
Authors: Serge P Eholie, Raoul Moh, Aïda Benalycherif, Delphine Gabillard, Frédéric Ello, Eugène Messou, Jacques Zoungrana, Ismaël Diallo, Mouhamadou Diallo, Guillaume Bado, Mamadou Cisse, Almoustapha I Maiga, Amani Anzian, Thomas-d'Aquin Toni, Malika Congo-Ouedraogo, Coumba Toure-Kane, Moussa Seydi, Daouda K Minta, Adrien Sawadogo, Lassana Sangaré, Joseph Drabo, Sophie Karcher, Jérome Le Carrou, Laure-Amelie de Monteynard, Gilles Peytavin, Audrey Gabassi, Pierre-Marie Girard, Marie-Laure Chaix, Xavier Anglaret, Roland Landman
Journal: The Lancet HIV (2019)
Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis
Authors: Catriona HM Jamieson, Robert P Hasserjian, Jason Gotlib, Jorge E. Cortes, Richard M. Stone, Moshe Talpaz, Jürgen Thiele, Scott J Rodig, Abhay Patki, Kaida Wu, Jingyang Wu, Olga Pozdnyakova
Journal: Blood (2013)
Clinical Significance of Additional Chromosomal Abnormalities In Ph-Positive and Ph-Negative Cells In Patients with Chronic Myeloid Leukemia Treated by Tyrosine Kinase Inhibitors
Authors: Anna G. Turkina, Olga Vinogradova, Alexandra Vorontsova, Ekaterina Chelysheva, Olga Lazareva, Galina Gusarova, Elena Aseeva, Nina Khoroshko
Journal: Blood (2011)
Romedepsin (RM), a Histone Deacytelase Inhibitor (HDACi), Significantly Increases the Expression of NKG2D Ligands, MIC A/B, In Pediatric Leukemia/Lymphoma Cells (LL), Resulting In Enhanced In Vitro and In Vivo NK Cytotoxicity In NOD-SCID Mice: Translational Approach for Adoptive NK Cell Targeted Immunotherapy
Authors: Prakash Satwani, Aniket Saha, Sejal Bavishi, Frances Zhao, Janet Ayello, Carmella van de Ven, Mitchell S. Cairo
Journal: Blood (2010)
Aplidin® (Plitidepsin) Activity In Peripheral T-Cell Lymphoma (PTCL): Final Results
Authors: Christophe Fermé, Maria Victoria Mateos, Sergio Szyldergemajn, Claudia S. Corrado, Emanuele Zucca, Sonia Extremera, Alessandro M. Gianni, Andrea Vandermeeren, Vincent Ribrag
Journal: Blood (2010)
Clinical Significance of Apoptosis in Chronic Lymphocytic Leukemia (CLL)
Authors: Giovanni Del Poeta, Maria Ilaria Del Principe, Michele Dal Bo, Francesco Buccisano, Dario Ragusa, Federico Pozzo, Pietro Bulian, Luca Maurillo, Davide Rossi, Adriano Venditti, Paolo de Fabritiis, Gianluca Gaidano, Sergio Amadori, Valter Gattei
Journal: Blood (2014)
Do Early Events Excluding Patients with Acute Promyelocytic Leukemia (APL) From Trial Enrollment Modify Treatment Result Evaluation? Real-Life Management of 100 Patients Referred to the University Hospital Saint-Louis Between 2000 and 2010.
Authors: Jean-Baptiste Micol, Emmanuel Raffoux, Nicolas Boissel, Etienne Lengliné, Emmanuel Canet, Thierry Leblanc, Marie-Thérèse Daniel, Adrienne de Labarthe, Odile Maarek, Bruno Cassinat, Christine Chomienne, Lionel Adès, André Baruchel, Laurent Degos, Elie Azoulay, Hervé Dombret
Journal: Blood (2010)
PFS2 In Elderly Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The MM-015 Study
Authors: Meletios A. Dimopoulos, Maria Teresa Petrucci, Robin Foà, John V. Catalano, Martin Kropff, Zhinuan Yu, Lara Grote, Christian J. Jacques, Antonio Palumbo
Journal: Blood (2013)
Whole-Exome Sequencing Of Adult Philadephia-Negative Acute Lymphoblastic Leukemia From Diagnosis To Relapse After Allogeneic Hematopoietic Stem Cell Transplantation Reveals Clonal Evolution and Relapse-Associated Mutated Genes
Authors: Haowen Xiao, Yi Luo, Xiaoyu Lai, Jimin Shi, Yamin Tan, Jingsong He, Wanzhuo Xie, Weiyan Zheng, Li-Mengmeng Wang, Shan Fu, Yebo Wang, Xiujin Ye, Xiaohong Yu, Zhen Cai, He Huang
Journal: Blood (2013)
Association Between Serum Ferritin and Liver Iron Concentration with Cardiac Iron in Pediatric Thalassemia Major Patients
Authors: Alessia Pepe, Antonella Meloni, Maddalena Casale, Maria Giovanna Neri, Pier Paolo Bitti, Silvia Macchi, Giovanni Roberto Giugno, Lucia De Franceschi, Massimiliano Missere, Patrizia Toia, Vincenzo Positano, Aldo Filosa
Journal: Blood (2015)
Targeted Therapy with Arsenic Trioxide and Interferon alpha Eradicates Leukemic Cells in SCID Mice Model of Adult T-Cell Leukemia/Lymphoma.
Authors: Hiba El Hajj, Hideki Hasegawa, Marwan El-Sabban, Ghazi Zaatari, Shehrazad Saab, Rami Mahfouz, Rihab Nasr, Youmna Kfoury, Olivier Hermine, Hugues de Thé, William Hall, Ali Bazarbachi
Journal: Blood (2007)
Next Generation Exome Sequencing for Identification of the Gene Mutations Associated with Loss of Heterozygozity on Chromosome 7 In Myeloid Malignancies
Authors: Yuka Sugimoto, Hideki Makishima, Hadrian Szpurka, Anna Jankowska, Kathryn Guinta, Ramon V. Tiu, Christine L. O'Keefe, Alison R Moliterno, Michael A McDevitt, Hideki Muramatsu, Seiji Kojima, Mehdi Keddache, Jaroslaw Maciejewski
Journal: Blood (2010)
Diverse Functional Implications of ADAMTS13 Gene Mutations in Patients with TTP and Congenital Deficiency.
Authors: Roberta Donadelli, Federica Banterla, Cristina Capoferri, Miriam Galbusera, Zaverio M. Ruggeri, Sara Bucchioni, Marina Noris, Giuseppe Remuzzi
Journal: Blood (2004)
Targeting Putative Mu Opioid/Chemokine Receptor Type 5 Heteromers Potently Attenuates Nociception in a Murine Model of Sickle Cell Disease
Authors: Giuseppe Cataldo, Mary M. Lunzer, Donald A. Simone, Eyup Akgün, John D. Belcher, Gregory M Vercellotti, Philip S. Portoghese
Journal: Blood (2015)
Comparison of Early Post-Transplant Outcomes in Ex Vivo αβ+ T Cell-Depleted Haploidentical HSCT with or without Pharmacologic Gvhd Prophylaxis
Authors: Eun Seok Choi, Sung Han Kang, Hyery Kim, Kyung-Nam Koh, Ho Joon Im, Jong Jin Seo, Jin Kyung Suh
Journal: Blood (2016)
Second-line treatment of HER2+ metastatic breast cancer (MBC): Trastuzumab (T) beyond progression or lapatinib (L)? A retrospective database study.
Authors: Rinat Yerushalmi, Ilan Feldhamer, Sari Greenberg-Dotan, Haim Bitterman, Ariel Hammerman
Journal: Journal of Clinical Oncology (2013)

639 Background: L and T “beyond progression” (TBP) for MBC pts who progressed on 1 st line therapy with T, are both reimbursed in Israel since 1/2010. The relative efficacy of L vs. T when combined with chemotherapy in 2 nd line therapy for HER2+ MBC is unknown. In this retrospective database study we compared outcomes of 2 nd line L or TBP, in the daily practice ("real life") in Israel. Methods: Using the computerized databases of Clalit Health Services' (CHS), Israel's largest health care provider, we identified all MBC pts that received 2 nd line anti HER2 therapy, with either L or TBP after a 1 st line protocol containing T, between 1/1/2010 and 31/12/2011. Pts characteristics and treatments were retrieved. The primary end point was overall survival (OS) defined as the time interval between date of initiation of 2 nd line anti HER2 therapy and death or last day of follow-up. Secondary endpoint was progression free survival (PFS), defined as duration of 2 nd line therapy. Results: The study population included 83 pts (28 L and 55 TBP). Mean age (59.9 vs. 61.4) and average Charlson co-morbidity index score (6.54 vs. 6.13) were similar between the cohorts. The groups differed in rates of prior adjuvant T (32.1% vs. 10.9%, p=0.017). The interim cutoff date for analysis was 31/12/2012 (allowing at least 12 months of follow-up). Median OS was 10.0 months for L pts (95% CI: 7.41–12.59) and was not reached for TBP, with a total of 31 deaths: 19 [67.9%] in the L group and 22 [40.0%] in the TBP group. A Cox regression showed an adjusted hazard ratio (HR) of 1.44 (95% CI 0.74-2.81), not significant (p=0.28).Prior adjuvant therapy with T was found to be a significant cofounder; HR=3.16 (95% CI 1.52-6.56). Median PFS was 6.0 months (95% CI: 4.31–7.69) for L and 7.0 months (95% CI: 4.30-9.70) for TBP, with a Cox regression adjusted HR of 0.87 (95% CI: 0.50-1.52), not statistically significant (p=0.87). Conclusions: In this retrospective database analysis, our interim results suggest no statistically significant difference in OS and PFS between L and TBP, as 2nd line therapy for HER2+ MBC, however the data showed a strong trend toward a survival benefit with TBP. A longer follow-up is required.
Azacitidine and Lenalidomide Combination In Higher-Risk Myelodysplastic Syndromes-Preliminary Results Of The Vilen-01 Protocol
Authors: Moshe Mittelman, Kalman Filanovsky, Hanna Rosenbaum, Pia Raanani, Andrei Braester, Neta Goldschmidt, Ilana Hellman, Ilya Kirgner, Chava Perri, Howard S Oster
Journal: Blood (2013)
Intravenous Compared to Oral Busulfan with Cyclophophamide for Allogeneic Hematopoietic Progenitor Cell Transplant Conditioning for AML and MDS.
Authors: Ronald Sobecks, Lisa Rybicki, Matt Kalaycio, Robert Dean, Steven Andresen, Brad Pohlman, Brian J. Bolwell, Edward A. Copelan
Journal: Blood (2010)
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
Authors: Philippe Armand, Scott Rodig, Vladimir Melnichenko, Catherine Thieblemont, Kamal Bouabdallah, Gayane Tumyan, Muhit Özcan, Sergio Portino, Laura Fogliatto, Maria D. Caballero, Jan Walewski, Zafer Gulbas, Vincent Ribrag, Beth Christian, Guilherme Fleury Perini, Gilles Salles, Jakub Svoboda, Jasmine Zain, Sanjay Patel, Pei-Hsuan Chen, Azra H. Ligon, Jing Ouyang, Donna Neuberg, Robert Redd, Arkendu Chatterjee, Arun Balakumaran, Robert Orlowski, Margaret Shipp, Pier Luigi Zinzani
Journal: Journal of Clinical Oncology (2019)

PURPOSE Patients with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) have a poor prognosis, and their treatment represents an urgent and unmet need. Because PMBCL is associated with genetic aberrations at 9p24 and overexpression of programmed cell death-1 (PD-1) ligands (PD-L1), it is hypothesized to be susceptible to PD-1 blockade. METHODS In the phase IB KEYNOTE-013 (ClinicalTrials.gov identifier: NCT01953692 ) and phase II KEYNOTE-170 (ClinicalTrials.gov identifier: NCT02576990 ) studies, adults with rrPMBCL received pembrolizumab for up to 2 years or until disease progression or unacceptable toxicity. The primary end points were safety and objective response rate in KEYNOTE-013 and objective response rate in KEYNOTE-170. Secondary end points included duration of response, progression-free survival, overall survival, and safety. Exploratory end points included association between biomarkers and pembrolizumab activity. RESULTS The objective response rate was 48% (7 complete responses; 33%) among 21 patients in KEYNOTE-013 and 45% (7 complete responses; 13%) among 53 patients in KEYNOTE-170. After a median follow-up time of 29.1 months in KEYNOTE-013 and 12.5 months in KEYNOTE-170, the median duration of response was not reached in either study. No patient with complete response experienced progression, including 2 patients with complete response for at least 1 year off therapy. Treatment-related adverse events occurred in 24% of patients in KEYNOTE-013 and 23% of patients in KEYNOTE-170. There were no treatment-related deaths. Among 42 evaluable patients, the magnitude of the 9p24 gene abnormality was associated with PD-L1 expression, which was itself significantly associated with progression-free survival. CONCLUSION Pembrolizumab is associated with high response rate, durable activity, and a manageable safety profile in patients with rrPMBCL.
Biomarkers of iron metabolism facilitate clinical diagnosis in <i>M</i><i>ycobacterium tuberculosis</i> infection
Authors: Youchao Dai, Wanshui Shan, Qianting Yang, Jiubiao Guo, Rihong Zhai, Xiaoping Tang, Lu Tang, Yaoju Tan, Yi Cai, Xinchun Chen
Journal: Thorax (2019)

Background Perturbed iron homeostasis is a risk factor for tuberculosis (TB) progression and an indicator of TB treatment failure and mortality. Few studies have evaluated iron homeostasis as a TB diagnostic biomarker. Methods We recruited participants with TB, latent TB infection (LTBI), cured TB (RxTB), pneumonia (PN) and healthy controls (HCs). We measured serum levels of three iron biomarkers including serum iron, ferritin and transferrin, then established and validated our prediction model. Results We observed and verified that the three iron biomarker levels correlated with patient status (TB, HC, LTBI, RxTB or PN) and with the degree of lung damage and bacillary load in patients with TB. We then built a TB prediction model, neural network (NNET), incorporating the data of the three iron biomarkers. The model showed good performance for diagnosis of TB, with 83% (95% CI 77 to 87) sensitivity and 86% (95% CI 83 to 89) specificity in the training data set (n=663) and 70% (95% CI 58 to 79) sensitivity and 92% (95% CI 86 to 96) specificity in the test data set (n=220). The area under the curves (AUCs) of the NNET model to discriminate TB from HC, LTBI, RxTB and PN were all &gt;0.83. Independent validation of the NNET model in a separate cohort (n=967) produced an AUC of 0.88 (95% CI 0.85 to 0.91) with 74% (95% CI 71 to 77) sensitivity and 92% (95% CI 87 to 96) specificity. Conclusions The established NNET TB prediction model discriminated TB from HC, LTBI, RxTB and PN in a large cohort of patients. This diagnostic assay may augment current TB diagnostics.
Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age.
Authors: Meletios A. Dimopoulos, Panagiotis Repoussis, Evangelos Terpos, Maria Christina Kyrtsonis, Athanasios Zomas, Eirini Katodritou, Souzana Delibasi, Amalia Vassou, Athanasios Anagnostopoulos, Anastasia Pouli, Konstantinos Zervas, Dimitrios Margaritis, Nikolaos Anagnostopoulos, Alice G. Maniatis
Journal: Blood (2004)
Paroxysmal Nocturnal Hemoglobinuria Caused By Pigt Mutations; Atypical PNH
Authors: Yoshiko Murakami, Michi Kawamoto, Norimitsu Inoue, Makiko Osato, Shogo Murata, Sho Murase, Hajime Yoshimura, Yasutaka Ueda, Jun-Ichi Nishimura, Yuzuru Kanakura, Nobuo Kohara, Taroh Kinoshita
Journal: Blood (2016)
Next-Generation Sequencing (NGS)-Based Profiling of Idiopathic Cytopenia of Undetermined Significance (ICUS) Identifies a Subset of Patients with Genomic Similarities to Lower-Risk Myelodysplastic Syndrome (MDS)
Authors: Brian Kwok, Prashanti Reddy, Keming Lin, Rachel Flamholz, Aine Yung, Bashar Dabbas, Matthew McGinniss, Shareef Nahas, Julie Kines, Yin Xu
Journal: Blood (2014)